Literature DB >> 19625587

Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006).

A Mosam1, H Carrara, F Shaik, T Uldrick, A Berkman, J Aboobaker, H M Coovadia.   

Abstract

The aim of the study was to describe the temporal trends in the incidence of Kaposi's sarcoma (KS) in black South Africans in KwaZulu-Natal (KZN). The study was designed as a retrospective record review. The incidence of Kaposi's sarcoma was estimated using administrative records for patients receiving care for KS through public sector oncology clinics in KZN, 1983-2006. Annual age-standardized incidence rates were calculated using provincial census data for the denominator. Age-specific rates were calculated for the pre-AIDS (1983-1989) and for the generalized AIDS epidemic eras (2006). Age-standardized incidence of KS increased in KZN from <1:100,000 in 1990 to at least 15:100,000 in 2006; this increase was observed in both men and women. There was a shift in the peak age-specific incidence rates from the sixth decade of life in the pre-AIDS era to the fourth and fifth decades in the AIDS era. In conclusion, KS is a growing public health problem in KZN, South Africa. These data reinforce the need for comprehensive national access to and roll-out of antiretroviral drugs, given their success in prevention and treatment of KS in first-world settings.

Entities:  

Mesh:

Year:  2009        PMID: 19625587     DOI: 10.1258/ijsa.2008.008372

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  17 in total

1.  Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda.

Authors:  Lisa M Butler; Willy A Were; Steven Balinandi; Robert Downing; Sheila Dollard; Torsten B Neilands; Sundeep Gupta; George W Rutherford; Jonathan Mermin
Journal:  J Infect Dis       Date:  2011-01-26       Impact factor: 5.226

Review 2.  Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities.

Authors:  Susan E Krown
Journal:  Curr Opin Oncol       Date:  2011-09       Impact factor: 3.645

Review 3.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

Review 4.  Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low- and middle-income countries in Africa.

Authors:  Clement A Adebamowo; Corey Casper; Kishor Bhatia; Sam M Mbulaiteye; Annie J Sasco; Warren Phipps; Sten H Vermund; Susan E Krown
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

5.  Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.

Authors:  Thomas S Uldrick; Kathleen M Wyvill; Pallavi Kumar; Deirdre O'Mahony; Wendy Bernstein; Karen Aleman; Mark N Polizzotto; Seth M Steinberg; Stefania Pittaluga; Vickie Marshall; Denise Whitby; Richard F Little; Robert Yarchoan
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544

6.  A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.

Authors:  Anisa Mosam; Fahmida Shaik; Thomas S Uldrick; Tonya Esterhuizen; Gerald H Friedland; David T Scadden; Jamila Aboobaker; Hoosen M Coovadia
Journal:  J Acquir Immune Defic Syndr       Date:  2012-06-01       Impact factor: 3.731

7.  'RNA circles of influence' in Kaposi sarcoma.

Authors:  Dimitrios Tsitsipatis; Myriam Gorospe
Journal:  Ann Transl Med       Date:  2019-07

8.  A population-based study of how children are exposed to saliva in KwaZulu-Natal Province, South Africa: implications for the spread of saliva-borne pathogens to children.

Authors:  L M Butler; T B Neilands; A Mosam; S Mzolo; J N Martin
Journal:  Trop Med Int Health       Date:  2010-02-09       Impact factor: 2.622

9.  Kaposi's sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression.

Authors:  Johanna R Abend; Dhivya Ramalingam; Philippe Kieffer-Kwon; Thomas S Uldrick; Robert Yarchoan; Joseph M Ziegelbauer
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

10.  Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA.

Authors:  Takanobu Tagawa; Shaojian Gao; Vishal N Koparde; Mileidy Gonzalez; John L Spouge; Anna P Serquiña; Kathryn Lurain; Ramya Ramaswami; Thomas S Uldrick; Robert Yarchoan; Joseph M Ziegelbauer
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.